Breast cancer |
miR-100, miR-222, miR-125a-3p |
Pathogenesis, diagnosis, chemo-resistance |
[35,125,126] |
Leukemia |
miR-146, miR-138, miR-203, miR-30a, 135-b, 196-b, 181-c |
Autophagy, chemo-resistance |
[3,127,128] |
Prostate and endometrial carcinoma |
miR-204, miR-551b, 96, 183, 182, 153, 625, miR-141, 193b, 200c, 193a-3p, 205, 708, 365, 34a |
Tumor development and progression, diagnosis |
[56,129] |
Ovarian cancer |
miR-21, miR-24 miR-141, miR-200a, miR-200b, miR 200c, miR-203, miR -205, and miR-214 |
Diagnostic marker |
[54,130] |
Pancreatic cancer |
miR-203 |
IL-12, TNF-α suppression |
[98] |
Lung cancer, leukemia, head and neck cancer |
miR-17-3p, 21, 106a, 146, 155, 191, 192, 203, 205, 210, 12, 214, 451 |
Diagnostic marker, chemo-resistance |
[131-134] |
Esophageal cancer |
miR-21, miR221 |
Tumor progression, chemo-resistance |
[135,136] |
Lung cancer |
miR-21 |
Chemo-resistance |
[137] |
Glioblastoma multiform |
miR-9 |
Temozolomide resistance |
[46] |
Cervical cancer |
miR-25 |
Cisplatin resistance |
[134] |
Gastric cancer |
miR-20, miR-19b-3p, miR-106a-5p |
Cisplatin resistance |
[138] |
Liver cancer |
miR-9-3p |
Diagnosis biomarker |
[65] |
Ovarian cancer |
mir-21, miR-100 |
Cell signaling |
[139,140] |
Lung cancer |
miR940, miR-23a |
Tumorigenesis, intercellular communication |
[141,142] |